

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee
Summary of Main Points from the Meeting held on the 10th February 2014

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the December 2013 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Individual funding requests

Teriparatide for osteoporosis with multiple vertebral compression fractures

Approved

Acitretin liquid for paediatric patient with Erythroderma

Noted

Previously approved by the Pharmacoeconomic Board.

Tolvaptan profound hyponatraemia associated with SIADH

Noted

Previously approved by the Pharmacoeconomic Board.

Ex-panel

Alteplase (cathflo[®])

Formulation of Alteplase specifically formulated and licensed for the management of occluded central lines.

Artesunate injection

Parenteral formulation of Riamet[®] for the treatment of Falciparum malaria in line with WHO guidance.

Removals

Norfloxacin 400mg tablets

Discontinued by the manufacturers.

5. Medicines Management/Trust Medicines Policy

- **Trust Medicines Policy: Section 11 – Medicine recalls**

Decision: Approved

Scheduled review with minor amendments.

- **Medicines Committee -Terms of Reference**

Decision: Approved

Updated to include recent changes in membership.

- **EPR RfC: Removal of text re. supplementary medication charts from EPR base screens**

Decision: Approved

The RfC was approved to remove the mandatory requirement for supplementary medication charts to be used for all patients. Supplementary drug charts will continue to be used only for patients received medication via syringe drivers.

7. NICE TA Guidance

NICE Guidance January 2013

TA303 – Teriflunomide for treating relapsing–remitting multiple sclerosis

Teriflunomide is recommended for treating adults with active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), **only if:**

- 1) they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis **and**
- 2) the manufacturer provides teriflunomide with the discount agreed in the patient access scheme.

Added to the Formulary in line with NICE Guidance

8. IVIG Update

The panel noted the IVIG report.

There were 10 IVIG issues in December 2013, with 4 new requests:

- One for Guillain Barre Syndrome (Red indication)
- One for Haemolytic disease of the fetus and newborn (Red indication)
- One for Idiopathic Thrombocytopenic Purpura (Red indication)
- One for Myasthenia Gravis (Blue indication)

There were 11 IVIG issues in January 2014, with 3 new requests:

- One for inflammatory myopathies (Blue indication)
- One for Autoimmune haemolytic anaemia (Blue indication)

One for Pparaneoplastic Disorder (Grey indication) (Approved by the Pharmacoeconomic Board. IFR form completed and submitted. Awaiting a response.

9. Items for Noting

- **NMP Audit Report 2013**

Co-ordinated and presented by CB. Results demonstrate NMPs perform to a high level and work within their professional boundaries as

Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Committee

set out by regulatory and professional standards. Patient satisfaction of the service provided by NMPs is favourable.

- **Antidote availability for Emergency Departments**

Updated guidance regarding poison antidote availability produced by the National Poisons Information Service and Specialist Pharmacy Service is now available. Pharmacy are in collaboration with ED to update stock holding in line with this updated guidance. Findings will be labelled at a future Medicines Committee meeting to provide assurance of completed action.

- **NWL Red List Dec 2013**

Noted

- **PGD Tracker Jan 2014**

Noted

- **NMP Register Nov 2013**

Noted

- **HIV Sub-Committee meeting minutes Oct 2013**

Noted

- **HIV Sub-Committee meeting minutes Nov 2013**

Noted

- **MHRA Drug Safety Update Dec 2013**

Noted

- **MHRA Drug Safety Update Jan 2014**

Noted.

Rituximab: Screening for Hepatitis B virus is now recommended for all patients before starting treatment with Rituximab

Action: Letter to be drafted and forwarded to those clinicians who prescribe rituximab for non-cancer indications.

9. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee:

- Medicines Committee Summary Notes - December 2013
- Medicines Committee Terms of Reference - February 2014

10. AOB

The pharmacy discharge prescribing transcribing policy is currently an opt-in policy for consultants. A proposal has been put forward by Pharmacy to change this to an opt-out policy as the general feeling is that the vast majority of consultants would be happy for a pharmacist to transcribe discharge prescriptions on behalf of their team to speed up discharge.

11. Date of the next meeting

Monday 10th February 2014, 8.00 - 9.00 - Boardroom, Lower Ground Floor

Closing date for papers: Friday 14th February 2014